## Marco Zecca

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6615234/publications.pdf

Version: 2024-02-01

16451 31849 14,290 347 64 101 citations h-index g-index papers 352 352 352 13425 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood, 2003, 102, 814-819.	1.4	515
2	Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood, 2003, 101, 2137-2143.	1.4	355
3	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood, 2017, 129, 1548-1556.	1.4	340
4	Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood, 2016, 127, 1387-1397.	1.4	304
5	Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood, 2005, 105, 410-419.	1.4	291
6	Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood, 2003, 101, 3857-3861.	1.4	278
7	Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood, 2011, 117, 6673-6680.	1.4	263
8	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood, 2009, 114, 1859-1863.	1.4	260
9	The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood, 2005, 106, 2183-2185.	1.4	247
10	Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroidâ€refractory, grade <scp>III</scp> – <scp>IV</scp> acute graftâ€versusâ€host disease. British Journal of Haematology, 2013, 163, 501-509.	2.5	213
11	lmatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood, 2009, 114, 709-718.	1.4	210
12	Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood, 2002, 100, 1192-1200.	1.4	201
13	Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation. American Journal of Transplantation, 2007, 7, 1648-1655.	4.7	192
14	Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. British Journal of Haematology, 2003, 122, 118-127.	2.5	174
15	Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood, 2012, 120, 473-476.	1.4	170
16	Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, 2013, 122, 170-178.	1.4	162
17	Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010. Bone Marrow Transplantation, 2016, 51, 536-541.	2.4	159
18	Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplantation, 2011, 46, 200-207.	2.4	154

#	Article	IF	CITATIONS
19	Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood, 2000, 95, 1572-1579.	1.4	153
20	Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood, 2001, 97, 3995-3997.	1.4	147
21	Posttransplant De Novo Donor-Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody-Mediated Rejection. American Journal of Transplantation, 2012, 12, 3355-3362.	4.7	142
22	KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood, 2014, 124, 2744-2747.	1.4	132
23	Extracorporeal photochemotherapy for treatmentof acute and chronic GVHD in childhood. Transfusion, 2001, 41, 1299-1305.	1.6	131
24	Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood, 2006, 107, 2984-2992.	1.4	123
25	Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2015, 135, 988-997.e6.	2.9	123
26	Analysis of immune reconstitution in children undergoing cord blood transplantation. Experimental Hematology, 2001, 29, 371-379.	0.4	119
27	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia, 2015, 29, 396-405.	7.2	114
28	Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood Journal of Clinical Oncology, 1997, 15, 566-573.	1.6	110
29	Extracorporeal photochemotherapy in graftâ€versusâ€host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfusion, 2010, 50, 1359-1369.	1.6	106
30	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	5.8	103
31	Unrelated donor vs HLA-haploidentical α∫β T-cell– and B-cell–depleted HSCT in children with acute leukemia. Blood, 2018, 132, 2594-2607.	1.4	101
32	Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood, 2010, 116, 3766-3769.	1.4	99
33	Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia, 2011, 25, 455-462.	7.2	98
34	Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood, 2020, 136, 1201-1211.	1.4	97
35	Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia, 2002, 16, 2228-2237.	7.2	94
36	Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood, 2011, 117, 4871-4880.	1.4	94

#	Article	IF	CITATIONS
37	Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget, 2014, 5, 2052-2064.	1.8	92
38	Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with longâ€ŧerm observation followâ€up. British Journal of Haematology, 2008, 140, 197-205.	2.5	90
39	Clofarabine, cyclophosphamide and etoposide as singleâ€course reâ€induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. British Journal of Haematology, 2009, 147, 371-378.	2.5	88
40	Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 2131-2136.	3.8	86
41	Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4â°' Subset Dynamics and Correlates with Remission State. Journal of Immunology, 2011, 186, 4490-4499.	0.8	85
42	Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients. American Journal of Transplantation, 2016, 16, 2106-2116.	4.7	85
43	Children with cancer in the time of COVIDâ€19: An 8â€week report from the six pediatric oncoâ€hematology centers in Lombardia, Italy. Pediatric Blood and Cancer, 2020, 67, e28410.	1.5	82
44	Minimal residual disease is an important predictive factor of outcome in children with relapsed â€'high-risk' acute lymphoblastic leukemia. Leukemia, 2008, 22, 2193-2200.	7.2	81
45	Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood, 2013, 122, 2135-2141.	1.4	79
46	Molecular and clinical heterogeneity in CLCN7-dependent osteopetrosis: report of 20 novel mutations. Human Mutation, 2010, 31, E1071-E1080.	2.5	77
47	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica, 2014, 99, 865-872.	3.5	77
48	Cord blood transplantation provides better reconstitution of hematopoietic reservoir compared with bone marrow transplantation. Blood, 2003, 102, 1138-1141.	1.4	76
49	Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. Journal of Clinical Immunology, 1995, 15, 137-144.	3.8	75
50	Autoimmune Hematological Diseases after Allogeneic Hematopoietic Stem Cell Transplantation in Children: An Italian Multicenter Experience. Biology of Blood and Marrow Transplantation, 2014, 20, 272-278.	2.0	75
51	Incidence and treatment of hemorrhagic cystitis in children given hematopoietic stem cell transplantation: a survey from the Italian association of pediatric hematology oncology–bone marrow transplantation group. Bone Marrow Transplantation, 2003, 32, 925-931.	2.4	74
52	B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Experimental Hematology, 2005, 33, 480-486.	0.4	74
53	Gene Expression–Based Classification As an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia. Journal of Clinical Oncology, 2010, 28, 1919-1927.	1.6	74
54	Late pulmonary sequelae after childhood bone marrow transplantation. Thorax, 1999, 54, 131-135.	5.6	73

#	Article	IF	CITATIONS
55	Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 807-811.	6.7	71
56	Molecular basis of Diamond-Blackfan anemia: new findings from the Italian registry and a review of the literature. Haematologica, 2004, 89, 480-9.	3.5	71
57	The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group. Haematologica, 2007, 92, 1381-1388.	3.5	70
58	Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood, 2014, 123, 1470-1478.	1.4	69
59	Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study. Biology of Blood and Marrow Transplantation. 2016. 22. 902-909.	2.0	69
60	Busulfan. Annals of Pharmacotherapy, 1994, 28, 1055-1062.	1.9	68
61	Donor/recipient mixed chimerism does not predict graft failure in children with Â-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica, 2008, 93, 1859-1867.	3.5	68
62	Treosulfanâ€based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. British Journal of Haematology, 2015, 169, 726-736.	2.5	68
63	Lung Function Abnormalities After Bone Marrow Transplantation in Children. Chest, 2001, 120, 1900-1906.	0.8	67
64	Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood, 2003, 101, 5053-5060.	1.4	65
65	Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood, 2012, 119, e96-e99.	1.4	65
66	Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica, 2008, 93, 1694-1701.	3 <b>.</b> 5	62
67	A Prospective Study on Children with Initial Diagnosis of Transient Hypogammaglobulinemia of Infancy: Results from the Italian Primary Immunodeficiency Network. International Journal of Immunopathology and Pharmacology, 2008, 21, 343-352.	2.1	61
68	The isochromosome i(7)(q10) carrying c.258+2t>c mutation of the SBDS gene does not promote development of myeloid malignancies in patients with Shwachman syndrome. Leukemia, 2009, 23, 708-711.	7.2	61
69	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. American Journal of Hematology, 2013, 88, 581-588.	4.1	61
70	Haematopoietic stem cell transplantation for Diamond Blackfan anaemia: a report from the Italian Association of Paediatric Haematology and Oncology Registry. British Journal of Haematology, 2014, 165, 673-681.	<b>2.</b> 5	61
71	Treosulfanâ€based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. British Journal of Haematology, 2008, 143, 548-551.	2.5	60
72	Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood, 2008, 111, 966-967.	1.4	60

#	Article	IF	CITATIONS
73	Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 1126-1136.	10.7	58
74	Effect of eradication of <i>Helicobacter pylori</i> in children with chronic immune thrombocytopenia: A prospective, controlled, multicenter study. Pediatric Blood and Cancer, 2011, 56, 273-278.	1.5	57
75	Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro-Oncology, 2005, 7, 41-48.	1.2	56
76	Management of Chronic Childhood Immune Thrombocytopenic Purpura: AIEOP Consensus Guidelines. Acta Haematologica, 2010, 123, 96-109.	1.4	56
77	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Annals of Oncology, 2012, 23, 435-441.	1.2	55
78	Notch1 regulates chemotaxis and proliferation by controlling the CCâ€chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. Journal of Pathology, 2012, 226, 713-722.	4.5	54
79	Prognostic significance of flowâ€cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the <scp>AIEOP</scp> â€ <scp>AML</scp> 2002/01 study protocol. British Journal of Haematology, 2017, 177, 116-126.	2.5	54
80	Pulmonary complications and respiratory function after bone marrow transplantation in children. European Respiratory Journal, 1997, 10, 2301-2306.	6.7	53
81	Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica, 2007, 92, 1186-1193.	3.5	53
82	Monitoring of Human Cytomegalovirus and Virus-Specific T-Cell Response in Young Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. PLoS ONE, 2012, 7, e41648.	2.5	53
83	Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). Blood Cells, Molecules, and Diseases, 2015, 55, 40-47.	1.4	53
84	Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. British Journal of Haematology, 2018, 183, 110-118.	2.5	53
85	Role of magnetic resonance imaging in the diagnosis and prognosis of growth hormone deficiency. Clinical Endocrinology, 1996, 45, 21-26.	2.4	52
86	Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood, 2004, 104, 281-289.	1.4	52
87	HLA-Haploidentical T Cell–Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Children with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2014, 20, 571-576.	2.0	52
88	Thymic function recovery after unrelated donor cord blood or T-cell depleted HLA-haploidentical stem cell transplantation correlates with leukemia relapse. Frontiers in Immunology, 2013, 4, 54.	4.8	51
89	Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study Bone Marrow Transplantation, 2015, 50, 181-188.	2.4	51
90	Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort. Journal of Allergy and Clinical Immunology, 2022, 149, 1744-1754.e8.	2.9	51

#	Article	IF	CITATIONS
91	Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders. BMC Medical Genomics, 2019, 12, 49.	1.5	50
92	Immunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of Alloimmunity. Clinical and Developmental Immunology, 2013, 2013, 1-6.	3.3	49
93	BCR-ABL–specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. Blood, 2017, 129, 582-586.	1.4	49
94	Longâ€term followâ€up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. British Journal of Haematology, 2009, 144, 552-558.	2.5	48
95	Human rhinovirus and human respiratory enterovirus (EV68 and EV104) infections in hospitalized patients in Italy, 2008–2009. Diagnostic Microbiology and Infectious Disease, 2012, 73, 162-167.	1.8	48
96	Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia, 2007, 21, 556-560.	7.2	47
97	Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. Haematologica, 2019, 104, e543-e546.	3.5	47
98	Germâ€line mutation of the <i>NRAS</i> gene may be responsible for the development of juvenile myelomonocytic leukaemia. British Journal of Haematology, 2009, 147, 706-709.	2.5	46
99	Bone marrow stromal cells from $\hat{l}^2$ -thalassemia patients have impaired hematopoietic supportive capacity. Journal of Clinical Investigation, 2019, 129, 1566-1580.	8.2	46
100	Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen. British Journal of Haematology, 2002, 119, 573-574.	2.5	45
101	Shwachman syndrome as mutator phenotype responsible for myeloid dysplasia/neoplasia through karyotype instability and chromosomes 7 and 20 anomalies. Genes Chromosomes and Cancer, 2006, 45, 375-382.	2.8	45
102	No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood, 2011, 118, 6683-6690.	1.4	45
103	European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. Pediatric Blood and Cancer, 2016, 63, 139-148.	1.5	45
104	Total Body Irradiation, Thiotepa, and Cyclophosphamide as a Conditioning Regimen for Children With Acute Lymphoblastic Leukemia in First or Second Remission Undergoing Bone Marrow Transplantation With HLA-Identical Siblings. Journal of Clinical Oncology, 1999, 17, 1838-1838.	1.6	44
105	Pre―and postâ€transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 180, 680-693.	2.5	44
106	Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1629-1642.	2.0	44
107	Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing. Bone Marrow Transplantation, 2003, 31, 987-993.	2.4	43
108	Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation. Clinical Pharmacology and Therapeutics, 1993, 54, 45-52.	4.7	42

#	Article	IF	Citations
109	Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. Experimental Hematology, 2006, 34, 934-942.	0.4	42
110	Incidence of, and Risk Factors for, Nosocomial Infections Among Hematopoietic Stem Cell Transplantation Recipients, With Impact on Procedure-Related Mortality. Infection Control and Hospital Epidemiology, 2001, 22, 510-517.	1.8	41
111	Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients. British Journal of Dermatology, 2010, 162, 404-409.	1.5	41
112	Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 467-474.	2.0	41
113	Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. Stem Cells Translational Medicine, 2021, 10, 636-642.	3.3	40
114	Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy. Biology of Blood and Marrow Transplantation, 2018, 24, 1223-1231.	2.0	39
115	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica, 2015, 100, 315-323.	3.5	38
116	Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Annals of Hematology, 2015, 94, 297-306.	1.8	38
117	Results of AIEOP LNHâ€97 protocol for the treatment of anaplastic large cell lymphoma of childhood. Pediatric Blood and Cancer, 2012, 59, 828-833.	1.5	37
118	Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2002, 29, 995-998.	2.4	36
119	T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood, 2004, 103, 4322-4329.	1.4	36
120	Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica, 2014, 99, 656-663.	3.5	36
121	Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960–1999 and registered in the Italian Off-Therapy Registry. European Journal of Cancer, 2019, 110, 86-97.	2.8	36
122	Rituximab (Anti-CD20 Monoclonal Antibody) in Children with Chronic Refractory Symptomatic Immune Thrombocytopenic Purpura: Efficacy and Safety of Treatment. International Journal of Hematology, 2006, 84, 48-53.	1.6	35
123	Preliminary study in a new protocol for the treatment of oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) and chemotherapy (CT). Lasers in Medical Science, 2017, 32, 1423-1428.	2.1	35
124	Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association–Hematopoietic Stem Cell Transplantation Group. Biology of Blood and Marrow Transplantation, 2019, 25, 313-320.	2.0	35
125	A 20â€year long term experience of the Italian Diamondâ€Blackfan Anaemia Registry: <i>RPS</i> and <i>RPL</i> genes, different faces of the same disease?. British Journal of Haematology, 2020, 190, 93-104.	2.5	35
126	Growth in Children after Bone Marrow Transplantation. Hormone Research, 1993, 39, 122-126.	1.8	34

#	Article	IF	Citations
127	<i>RASA4</i> i>undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics, 2014, 9, 1252-1260.	2.7	34
128	Resolution of immune haemolytic anaemia with allogeneic bone marrow transplantation after an unsuccessful autograft. British Journal of Haematology, 1999, 106, 1063-1064.	2.5	33
129	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood, 2008, 111, 1124-1127.	1.4	33
130	Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation, 2018, 24, 1699-1706.	2.0	33
131	Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn ErrorsÂWorking Party analysis. Blood, 2022, 139, 2066-2079.	1.4	33
132	Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. British Journal of Haematology, 2005, 131, 483-486.	2.5	31
133	Modulating effect of human growth hormone on tumour necrosis factor-alpha and interleukin-1beta. European Journal of Endocrinology, 1998, 138, 640-643.	3.7	30
134	Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplantation, 2002, 29, 93-100.	2.4	30
135	Management of Acute Childhood Idiopathic Thrombocytopenic Purpura according to AIEOP Consensus Guidelines: Assessment of Italian Experience. Acta Haematologica, 2008, 119, 1-7.	1.4	30
136	Advanced pediatric myelodysplastic syndromes: Can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?. Pediatric Blood and Cancer, 2009, 52, 357-363.	1.5	30
137	Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry. Haematologica, 2013, 98, 1273-1281.	3.5	30
138	RANKL Cytokine: From Pioneer of the Osteoimmunology Era to Cure for a Rare Disease. Clinical and Developmental Immunology, 2013, 2013, 1-9.	3.3	30
139	Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. Leukemia, 2014, 28, 1742-1745.	7.2	30
140	Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. Haematologica, 2016, 101, 884-890.	3.5	30
141	MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Oncotarget, 2016, 7, 55395-55408.	1.8	30
142	Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Advances, 2021, 5, 2901-2908.	5.2	29
143	Factors influencing post-transfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation. Leukemia, 2001, 15, 1885-1891.	7.2	28
144	Human Cytomegalovirus–Specific T Cell Reconstitution in Young Patients Receiving T Cell–Depleted, Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases, 2009, 199, 829-836.	4.0	28

#	Article	IF	CITATIONS
145	Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. Pharmacogenomics Journal, 2017, 17, 4-10.	2.0	28
146	Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. Bone Marrow Transplantation, 2020, 55, 1918-1927.	2.4	28
147	Recombinant human G SFâ€mobilized peripheral blood stem cells for second allogeneic transplant after bone marrow graft rejection in children. British Journal of Haematology, 1996, 92, 432-434.	2.5	27
148	A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 384-387.	2.4	27
149	Total-Body Irradiation and Melphalan Is a Safe and Effective Conditioning Regimen for Autologous Bone Marrow Transplantation in Children With Acute Myeloid Leukemia in First Remission. Journal of Clinical Oncology, 1999, 17, 3729-3735.	1.6	26
150	Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission. Bone Marrow Transplantation, 2003, 32, 325-331.	2.4	26
151	Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia, 2007, 21, 1108-1109.	7.2	26
152	T Cell Therapy for Nasopharyngeal Carcinoma. Journal of Cancer, 2011, 2, 341-346.	2.5	26
153	Vitiligo-Like Lesions and Diffuse Lightening of the Skin in a Pediatric Patient Treated with Imatinib Mesylate: A Noninvasive Colorimetric Assessment. Pediatric Dermatology, 2006, 23, 175-178.	0.9	25
154	Aberrant GM-CSF signal transduction pathway in juvenile myelomonocytic leukemia assayed by flow cytometric intracellular STAT5 phosphorylation measurement. Leukemia, 2009, 23, 791-793.	7.2	25
155	Toxoplasmosis disease in paediatric hematopoietic stem cell transplantation: do not forget it still exists. Bone Marrow Transplantation, 2017, 52, 1326-1329.	2.4	25
156	Transplant results in adults with Fanconi anaemia. British Journal of Haematology, 2018, 180, 100-109.	2.5	25
157	Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study. Bone Marrow Transplantation, 2019, 54, 1632-1642.	2.4	25
158	Treatment of chronic childhood immune thrombocytopenic purpura with intramuscular antiâ€D immunoglobulins. British Journal of Haematology, 1994, 88, 618-620.	2.5	24
159	Role of allogeneic bone marrow transplantation from an HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia. British Journal of Haematology, 1996, 92, 49-54.	2.5	24
160	Experts' considerations on <scp>HLA</scp> â€haploidentical stem cell transplantation. European Journal of Haematology, 2014, 93, 187-197.	2.2	24
161	Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. Bone Marrow Transplantation, 2021, 56, 2732-2741.	2.4	24
162	Management of Graft-Versus-Host Disease in Paediatric Bone Marrow Transplant Recipients. Paediatric Drugs, 2000, 2, 29-55.	3.1	23

#	Article	IF	CITATIONS
163	Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. British Journal of Haematology, 2001, 114, 951-953.	2.5	23
164	Conceiving a hematopoietic stem cell donor: twenty-five years after our decision to save a child. Haematologica, 2012, 97, 479-481.	3.5	23
165	Comprehensive characterization of mesenchymal stromal cells from patients with Fanconi anaemia. British Journal of Haematology, 2015, 170, 826-836.	2.5	23
166	Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Oncotarget, 2016, 7, 56746-56757.	1.8	23
167	Point of view of the Italians pediatric scientific societies about the pediatric care during the COVID-19 lockdown: what has changed and future prospects for restarting. Italian Journal of Pediatrics, 2020, 46, 142.	2.6	23
168	Adolescent and adult uterine volume and uterine artery Doppler blood flow among subjects treated with bone marrow transplantation or chemotherapy in pediatric age: aÂcase-control study. Fertility and Sterility, 2015, 103, 455-461.	1.0	22
169	Gastrointestinal tract carcinoma in pediatric and adolescent age: The Italian TREP project experience. Pediatric Blood and Cancer, 2017, 64, e26658.	1.5	22
170	Management of Nutritional Needs in Pediatric Oncology: A Consensus Statement. Cancers, 2022, 14, 3378.	3.7	22
171	Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls. Journal of Clinical Immunology, 1998, 18, 193-201.	3.8	21
172	Incompatibility for CD31 and human platelet antigens and acute graft-versus-host disease after bone marrow transplantation. British Journal of Haematology, 1999, 106, 723-729.	2.5	21
173	Hair Depigmentation and Vitiligo-like Lesions in a Leukaemic Paediatric Patient during Chemotherapy with Dasatinib. Acta Dermato-Venereologica, 2012, 92, 218-219.	1.3	21
174	Genomic alterations in human umbilical cord–derived mesenchymal stromal cells call for stringent quality control before any possible therapeutic approach. Cytotherapy, 2013, 15, 1362-1373.	0.7	21
175	The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS. Leukemia, 2014, 28, 189-192.	7.2	21
176	More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Working Party. Bone Marrow Transplantation, 2017, 52, 1071-1073.	2.4	21
177	Mutations of <i>SETBP1</i> and <i>JAK3</i> in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. Oncotarget, 2016, 7, 28914-28919.	1.8	21
178	Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation. Bone Marrow Transplantation, 2003, 31, 437-440.	2.4	20
179	Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood. Leukemia, 2013, 27, 1923-1925.	7.2	20
180	Combined cord blood and bone marrow transplantation from the same human leucocyte antigenâ€identical sibling donor for children with malignant and nonâ€malignant diseases. British Journal of Haematology, 2015, 169, 103-110.	2.5	20

#	Article	lF	CITATIONS
181	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. British Journal of Cancer, 2017, 116, 335-343.	6.4	20
182	Evaluation of growth hormone bioactivity using the Nb2 cell bioassay in children with growth disorders. Journal of Endocrinological Investigation, 1998, 21, 765-770.	3.3	19
183	Cellâ€cycle phases and genetic profile of bone marrowâ€derived mesenchymal stromal cells expanded in vitro from healthy donors. Journal of Cellular Biochemistry, 2011, 112, 1817-1821.	2.6	19
184	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1939-1948.	2.0	19
185	A Prospective Study of Hematologic Complications and Long-Term Survival of Italian Patients Affected by Shwachman-Diamond Syndrome. Journal of Pediatrics, 2020, 219, 196-201.e1.	1.8	19
186	Translocation (8;21) in two cases of refractory anemia with excess of blasts in transformation. Cancer Genetics and Cytogenetics, 1992, 58, 76-78.	1.0	18
187	Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia. Human Immunology, 2012, 73, 282-286.	2.4	18
188	Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia-Positive Acute Lymphoblastic Leukemia in Children and Adolescents: A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Biology of Blood and Marrow Transplantation, 2012, 18, 852-860.	2.0	18
189	Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation. British Journal of Haematology, 1993, 84, 752-754.	2.5	17
190	Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study. Bone Marrow Transplantation, 1998, 22, 743-750.	2.4	17
191	Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. Rheumatology, 1999, 38, 773-773.	1.9	17
192	Splenectomy in children with chronic ITP: Long-term efficacy and relation between its outcome and responses to previous treatments. Pediatric Blood and Cancer, 2006, 47, 742-745.	1.5	17
193	Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2011, 24, 339-349.	1.7	17
194	Outcomes after Unrelated Umbilical Cord Blood Transplantation for Children with Osteopetrosis. Biology of Blood and Marrow Transplantation, 2016, 22, 1997-2002.	2.0	17
195	Acquired Complement Regulatory Gene Mutations and Hematopoietic Stem Cell Transplant–Related Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 2017, 23, 1580-1582.	2.0	17
196	JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia. Leukemia, 2007, 21, 367-369.	7.2	16
197	Monosomy 7 in myeloid malignancies: parental origin and monitoring by real-time quantitative PCR. Leukemia, 2007, 21, 1833-1835.	7.2	16
198	Allogeneic Stem Cell Transplantation for Children With Acute Myeloid Leukemia in Second Complete Remission. Journal of Pediatric Hematology/Oncology, 2008, 30, 575-583.	0.6	16

#	Article	IF	CITATIONS
199	In vitro toxicity screening of magnetite nanoparticles by applying mesenchymal stem cells derived from human umbilical cord lining. Journal of Applied Toxicology, 2019, 39, 1320-1336.	2.8	16
200	Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives. Frontiers in Immunology, 2020, $11,567020$ .	4.8	16
201	Postnatal Variations of Growth Hormone Bioactivity and of Growth Hormone-Dependent Factors. JAMA Pediatrics, 1996, 150, 1068.	3.0	15
202	Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia. British Journal of Haematology, 2003, 120, 369-371.	2.5	15
203	Bartonella-related pseudomembranous angiomatous papillomatosis of the oral cavity associated with allogeneic bone marrow transplantation and oral graft-versus-host disease. British Journal of Dermatology, 2007, 157, 174-178.	1.5	15
204	A low thymic function is associated with leukemia relapse in children given T-cell-depleted HLA-haploidentical stem cell transplantation. Leukemia, 2012, 26, 1886-1888.	7.2	15
205	Gonadal and uterine function in female survivors treated by chemotherapy, radiotherapy, and/or bone marrow transplantation for childhood malignant and nonâ€malignant diseases. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 856-865.	2.3	15
206	Transplantation of cord blood progenitor cells can promote bone resorption in autosomal recessive osteopetrosis. Bone Marrow Transplantation, 1997, 20, 701-705.	2.4	14
207	Human alloantigen-specific anergic cells induced by a combination of CTLA4-Ig and CsA maintain anti-leukemia and anti-viral cytotoxic responses. Bone Marrow Transplantation, 2001, 27, 1263-1273.	2.4	14
208	Non-myeloablative stem cell transplantation for severe combined immunodeficiency - Omenn syndrome. British Journal of Haematology, 2004, 125, 406-407.	2.5	14
209	Single-Cell Cloning of Human, Donor-Derived Antileukemia T-Cell Lines for In vitro Separation of Graft-versus-Leukemia Effect from Graft-versus-Host Reaction. Cancer Research, 2006, 66, 7310-7316.	0.9	14
210	Allogeneic Hematopoietic Stem Cell Transplantation May Restore Gluten Tolerance in Patients With Celiac Disease. Journal of Pediatric Gastroenterology and Nutrition, 2013, 56, 422-427.	1.8	14
211	Arsenic trioxide and allâ€trans retinoic acid treatment for childhood acute promyelocytic leukaemia. British Journal of Haematology, 2019, 185, 360-363.	2.5	14
212	Stem cell transplantation for congenital dyserythropoietic anemia: an analysis from the European Society for Blood and Marrow Transplantation. Haematologica, 2019, 104, e335-e339.	3.5	14
213	The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Bone Marrow Transplantation, 2020, 55, 1946-1954.	2.4	14
214	Haploâ€identical or mismatched unrelated donor hematopoietic cell transplantation for <scp>Fanconi</scp> anemia: Results from the <scp>Severe Aplastic Anemia Working Party</scp> of the <scp>EBMT</scp> . American Journal of Hematology, 2021, 96, 571-579.	4.1	14
215	A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the & Defects &	1.5	13
216	Isomorphic cutaneous graftâ€versusâ€host disease reaction after ultraviolet exposure: clinical, histological and direct immunofluorescence studies of four alloâ€transplanted patients. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 913-918.	2.4	13

#	Article	IF	Citations
217	Does SPRED1 contribute to leukemogenesis in juvenile myelomonocytic leukemia (JMML)?. Blood, 2010, 115, 2557-2558.	1.4	13
218	Interactions between killer immunoglobulinâ€like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm. British Journal of Haematology, 2012, 156, 118-128.	2.5	13
219	Efficacy of Acitretin for Porokeratosis in a Child with Chronic Cutaneous Graft Versus Host Disease. Pediatric Dermatology, 2013, 30, 148-150.	0.9	13
220	Liver stiffness assessed by transient elastography in patients with $\hat{l}^2$ thalassaemia major. Annals of Hepatology, 2016, 15, 410-417.	1.5	13
221	The prognostic value of biological markers in paediatric Hodgkin lymphoma. European Journal of Cancer, 2016, 52, 33-40.	2.8	13
222	Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major. Annals of Hematology, 2022, 101, 655-665.	1.8	13
223	Recombinant human erythropoietin is effective in correcting erythropoietinâ€deficient anaemia after allogeneic bone marrow transplantation. British Journal of Haematology, 1992, 80, 545-549.	2.5	12
224	Cord blood transplantation in children with haematological malignancies. Best Practice and Research in Clinical Haematology, 2010, 23, 189-196.	1.7	12
225	Successful treatment of a classic Hodgkin lymphomaâ€type postâ€transplant lymphoproliferative disorder with tailored chemotherapy and Epstein–Barr virusâ€specific cytotoxic T lymphocytes in a pediatric heart transplant recipient. Pediatric Transplantation, 2013, 17, E168-73.	1.0	12
226	Whole exome sequencing in the differential diagnosis of Diamond-Blackfan anemia: Clinical and molecular study of three patients with novel RPL5 and mosaic RPS19 mutations. Blood Cells, Molecules, and Diseases, 2017, 64, 38-44.	1.4	12
227	Parental origin of the deletion del(20q) in Shwachmanâ€Diamond patients and loss of the paternally derived allele of the imprinted <i>L3MBTL1</i> gene. Genes Chromosomes and Cancer, 2017, 56, 51-58.	2.8	12
228	Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children. Bone Marrow Transplantation, 2019, 54, 275-283.	2.4	12
229	Recurrent genetic fusions redefine <i>MLL </i> germ line acute lymphoblastic leukemia in infants. Blood, 2021, 137, 1980-1984.	1.4	12
230	Frequency of donor cytotoxic T cell precursors does not correlate with occurrence of acute graft-versus-host disease in children transplanted using unrelated donors. Journal of Clinical Immunology, 1996, 16, 107-114.	3.8	11
231	Screening of novel genetic aberrations in pediatric acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Blood, 2012, 120, 3860-3862.	1.4	11
232	Persistent rhinovirus infection in pediatric hematopoietic stem cell transplant recipients with impaired cellular immunity. Journal of Clinical Virology, 2015, 67, 38-42.	3.1	11
233	Evolving Services for Adolescents with Cancer in Italy: Access to Pediatric Oncology Centers and Dedicated Projects. Journal of Adolescent and Young Adult Oncology, 2020, 9, 196-201.	1.3	11
234	Childhood cancer in Italy: background, goals, and achievements of the Italian Paediatric Hematology Oncology Association (AIEOP). Tumori, 2021, 107, 370-375.	1.1	11

#	Article	IF	CITATIONS
235	A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study. Bone Marrow Transplantation, 2021, 56, 2454-2463.	2.4	11
236	The immunosuppressive effect of human cytomegalovirus infection in recipients of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2005, 36, 503-509.	2.4	10
237	Quantitative ultrasound detects bone impairment after bone marrow transplantation in children and adolescents affected by hematological diseases. Bone, 2008, 43, 177-182.	2.9	10
238	Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2019, 184, 397-404.	2.5	10
239	Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 567531.	4.8	10
240	Comparison of Hodgkin's Lymphoma in Children and Adolescents. A Twenty Year Experience with MH'96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols. Cancers, 2020, 12, 1620.	3.7	10
241	Infusion of donor-derived peripheral blood leukocytes after transplantation of cord blood progenitor cells can increase the graft-versus-leukaemia effect. Leukemia, 1997, 11, 729-731.	7.2	9
242	HLA-identical umbilical cord blood transplantation from a sibling donor in juvenile myelomonocytic leukemia. Haematologica, 2009, 94, 302-304.	3.5	9
243	Ubiquitin-proteasome-rich cytoplasmic structures in neutrophils of patients with Shwachman-Diamond syndrome. Haematologica, 2012, 97, 1057-1063.	3.5	9
244	Successful T-cell–depleted Haploidentical Hematopoietic Stem Cell Transplantation in a Child With Dyskeratosis Congenita After a Fludarabine-based Conditioning Regimen. Journal of Pediatric Hematology/Oncology, 2015, 37, 322-326.	0.6	9
245	Posttransplant Soluble B-Cell Activating Factor Kinetics in Pediatric Recipients of First Kidney Allograft. Transplantation, 2015, 99, 243-249.	1.0	9
246	Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017. Blood, 2018, 132, 168-168.	1.4	9
247	The role of nutrition in children with cancer. Tumori, 2023, 109, 19-27.	1.1	9
248	Successful bone marrow transplantation in children with severe aplastic anemia using HLA-partially matched family donors. American Journal of Hematology, 1993, 42, 328-333.	4.1	8
249	Foreign children with cancer in Italy. Italian Journal of Pediatrics, 2011, 37, 44.	2.6	8
250	Differential outcome of neurological HCMV infection in two hematopoietic stem cell transplant recipients. BMC Infectious Diseases, 2012, 12, 238.	2.9	8
251	T-cell receptor $\hat{V^2}$ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS. Blood Cancer Journal, 2014, 4, e209-e209.	6.2	8
252	Microarray expression studies on bone marrow of patients with Shwachman-Diamond syndrome in relation to deletion of the long arm of chromosome 20, other chromosome anomalies or normal karyotype. Molecular Cytogenetics, 2020, 13, 1.	0.9	8

#	Article	IF	Citations
253	Rhabdomyosarcoma with Primary Osteolytic Lesions Simulating Non-Hodgkin's Lymphoma. Pediatric Hematology and Oncology, 1991, 8, 159-164.	0.8	7
254	Placental-Blood Transplantation. New England Journal of Medicine, 1997, 336, 68-70.	27.0	7
255	Expression of p75 chain of IL-2 receptor in the early immunological reconstitution after allogeneic bone marrow transplantation. Clinical and Experimental Immunology, 2008, 97, 510-516.	2.6	7
256	Mutational analysis of SHOC2, a novel gene for Noonan-like syndrome, in JMML. Blood, 2010, 115, 913-913.	1.4	7
257	Different outcomes of allogeneic hematopoietic stem cell transplant in a pair of twins affected by juvenile myelomonocytic leukemia. International Journal of Hematology, 2014, 99, 208-212.	1.6	7
258	Analysis of <i>KIR3DP1</i> Polymorphism Provides Relevant Information on Centromeric <i>KIR</i> Gene Content. Journal of Immunology, 2018, 201, 1460-1467.	0.8	7
259	Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study Journal of Clinical Oncology, 2019, 37, 10031-10031.	1.6	7
260	Congenital aggressive variant of Langerhans cells histiocytosis with CD56+/Eâ€Cadherinâ^' phenotype. Pediatric Blood and Cancer, 2009, 53, 1107-1110.	1.5	6
261	Immunotherapy against EBV-lymphoma in recipients of HSCT. Expert Review of Hematology, 2010, 3, 625-632.	2.2	6
262	Gene expression signatures of pediatric myelodysplastic syndromes are associated with risk of evolution into acute myeloid leukemia. Leukemia, 2012, 26, 1717-1719.	7.2	6
263	Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group. Transplantation, 2021, 105, 686-694.	1.0	6
264	Diagnostic Delay in Adolescents with Cancer During COVID-19 Pandemic: A New Price for Our Patients to Pay. Journal of Adolescent and Young Adult Oncology, 2022, 11, 316-319.	1.3	6
265	Refractory Cytopenia In Childhood (RCC) with Normal Karyotype Is Unlikely to Progress to Advanced MDS Under a Watch and Wait Strategy. Blood, 2010, 116, 4007-4007.	1.4	6
266	Recombinant human erythropoietin may correct erythropoietin-deficient hyporegenerative anaemia in children given cardiac transplantation. British Journal of Haematology, 1994, 88, 623-625.	2.5	5
267	Monitoring the Isochromosome i(7)(q10) in the Bone Marrow of Patients With Shwachman Syndrome by Real-time Quantitative PCR. Journal of Pediatric Hematology/Oncology, 2007, 29, 163-165.	0.6	5
268	Tuberculosis-induced haemophagocytic syndrome in a patient on haemodialysis treated with anti-thymocyte globulin [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2014, 18, 248-249.	1.2	5
269	Automated red blood cell depletion in ABO incompatible grafts in the pediatric setting. Transfusion and Apheresis Science, 2017, 56, 895-899.	1.0	5
270	Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis. Biology of Blood and Marrow Transplantation, 2017, 23, 96-102.	2.0	5

#	Article	IF	Citations
271	Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches. Cancers, 2021, 13, 1577.	3.7	5
272	Acute events in children with sickle cell disease in Italy during the COVIDâ€19 pandemic: useful lessons learned. British Journal of Haematology, 2021, 194, 851-854.	2.5	5
273	Children with Acute Leukemia Given Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Compatible Sibling, or an Unrelated Donor (UD) or an HLA-Haploidentical Relative after Alpha/Beta T-Cell Depletion Have a Comparable Outcome. Blood, 2015, 126, 195-195.	1.4	5
274	Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP) Tj ETQq0	0 (1.pgBT /0	Ov <b>e</b> rlock 10
275	Management of Graft-Versus-Host Disease in Paediatric Bone Marrow Transplant Recipients. Paediatric Drugs, 2000, 2, 29-55.	3.1	5
276	Identification of Biochemical and Molecular Markers of Early Aging in Childhood Cancer Survivors. Cancers, 2021, 13, 5214.	3.7	5
277	Transplantation of T-Cell Depleted Peripheral Blood Haematopoietic Stem Cells from an HLA-Disparate Family Donor for Children with Hematological Malignancies Blood, 2007, 110, 3071-3071.	1.4	5
278	Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy. Leukemia and Lymphoma, 2018, 59, 2612-2621.	1.3	4
279	Generation of donor-derived Wilms tumor antigen $1\hat{a}\in$ "specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study. Cytotherapy, 2019, 21, 958-972.	0.7	4
280	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25â€year Italian experience. British Journal of Haematology, 2021, 195, 278-283.	2.5	4
281	Busulfan/Fludarabine- or Treosulfan/Fludarabine-Based Conditioning Regimen in Patients with Wiskott-Aldrich Syndrome Given Allogeneic Hematopoietic Cell Transplantation — an EBMT Inborn Errors Working Party and Scetide Retrospective Analysis. Blood, 2018, 132, 2175-2175.	1.4	4
282	Imatinib Is Safe and Effective In Patients with Refractory Chronic Graft Versus Host Disease: Analysis of Two Consecutive Prospective GITMO* Studies.*Gruppo Italiano Trapianto Midollo Osseo. Blood, 2010, 116, 246-246.	1.4	4
283	JMML Revisited: Role Und Outcome of Hematopoietic Stem Cell Transplantation in Subtypes of Juvenile Myelomonocytic Leukemia (JMML). Blood, 2012, 120, 955-955.	1.4	4
284	Hematopoietic Stem Cell Transplantation from HLA Identical Sibling Forsickle Cell Disease an International Survey on Behalf of Eurocord-Monacord, EBMT Paediatric Disease Working Party and CIBMTR. Blood, 2015, 126, 541-541.	1.4	4
285	Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT. Bone Marrow Transplantation, 2022, 57, 817-823.	2.4	4
286	Streptococcus pneumoniaepharyngeal colonization in school-age children and adolescents with cancer. Human Vaccines and Immunotherapeutics, 2016, 12, 301-307.	3.3	3
287	Neonatal vesiculopustular eruption in Down syndrome and transient myeloproliferative disorder: A case report and review of the literature. Pediatric Dermatology, 2019, 36, 702-706.	0.9	3
288	Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience. Leukemia and Lymphoma, 2019, 60, 696-702.	1.3	3

#	Article	IF	CITATIONS
289	Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment Blood, 2006, 108, 2681-2681.	1.4	3
290	Clonal Evolution and Lack of BCR-ABL1 Mutations in Pediatric Ph+ ALL Patients Resistant/Refractory to Imatinib Treatment. Blood, 2015, 126, 2622-2622.	1.4	3
291	Steroid-Refractory Acute Gvhd in Children: Retrospective Analysis of the AIEOP HSCT Registry. Blood, 2018, 132, 4578-4578.	1.4	3
292	Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience. Cancers, 2022, 14, 1471.	3.7	3
293	Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA. Thrombosis and Haemostasis, 2021, , .	3.4	3
294	Chronic Graft-versus-host Disease and Non-melanoma Skin Cancer in Children: Report of Two Cases. Acta Dermato-Venereologica, 2008, 88, 623-623.	1.3	3
295	Juvenile chronic myelogenous leukemia: In vitro characterization before and after allogeneic bone marrow transplantation. Medical and Pediatric Oncology, 1995, 24, 166-170.	1.0	2
296	The strange case of the lost <i>NRAS</i> mutation in a child with juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2012, 59, 580-582.	1.5	2
297	High Performance Liquid Chromatography–Tandem Mass Spectrometry Method for Simultaneous Quantification of Caspofungin, Anidulafungin and Micafungin in Human Plasma for Feasible Applications in Pediatric Haematology/Oncology. Chromatographia, 2017, 80, 1035-1045.	1.3	2
298	VIVA (vinorelbine, ifosfamide, vincristine, actinomycinâ€D): A new regimen in the armamentarium of systemic therapy for highâ€risk rhabdomyosarcoma. Pediatric Blood and Cancer, 2020, 67, e28649.	1.5	2
299	Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adults with Chronic Granulomatous Disease (CGD): A Study of the Inborn Errors Working Party (IEWP) of the EBMT. Blood, 2018, 132, 970-970.	1.4	2
300	Acute Chest Syndrome in Children with Sickle Cell Disease in Italy: Results of a National Survey from the Italian Association of Pediatric Hematology Oncology (AIEOP). Blood, 2019, 134, 2301-2301.	1.4	2
301	Outcome of Children with All Given HSCT from Unrelated Volunteers Has Significantly Improved over Time and Now Is Comparable to That of Children Transplanted from an HLA-Identical Sibling Blood, 2004, 104, 2156-2156.	1.4	2
302	Allogeneic Stem Cell Transplantation for Children with Advanced Primary MDS: Results from the EWOG-MDS Study Group Employing a Pre-Transplant Preparative Regimen with Busulfan, Cyclophosphamide and Melphalan Blood, 2004, 104, 2300-2300.	1.4	2
303	Comparison Between Related T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (TCD-Haplo) and Umbilical Cord Blood Transplantation (UCBT) in Pediatric Patients with Acute Leukemia, a Eurocord, PDWP-EBMT Study. Blood, 2014, 124, 1215-1215.	1.4	2
304	Analysis of Risk Factors Influencing Outcomes After Unrelated Cord Blood Transplantation In Children with Juvenile Myelomonocytic Leukemia. An Eurocord, EBMT, EWOG-MDS, CIBMTR Study. Blood, 2010, 116, 533-533.	1.4	2
305	Outcome Of Unrelated Umbilical Cord Blood Transplantation For Children With Osteopetrosis: An Eurocord and Inborn Errors Working Party (IEWP)-EBMT Study. Blood, 2013, 122, 2100-2100.	1.4	2
306	A novel SLC4A1 mutation in a child with hereditary spherocytosis and distal renal tubular acidosis. Pediatric Blood and Cancer, 2022, 69, e29729.	1.5	2

#	Article	IF	CITATIONS
307	Sustained remission of immune-mediated red cell aplasia in a child after intravenous administration of gamma globulin. Journal of Pediatrics, 1994, 125, 403-405.	1.8	1
308	Chromosome anomalies in bone marrow as primary cause of aplastic or hypoplastic conditions and peripheral cytopenia: disorders due to secondary impairment of RUNX1 and MPL genes. Molecular Cytogenetics, 2012, 5, 39.	0.9	1
309	Evidence for CD19B–CD8T cell interactions in blood and tissues from patients with GvHD. Bone Marrow Transplantation, 2017, 52, 459-462.	2.4	1
310	Nationwide central diagnosis review for childhood solid tumors: From concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project. Pediatric Blood and Cancer, 2019, 66, e27749.	1,5	1
311	FANCA, TP53, and del(5q)/RPS14 alterations in a patient with T-cell non-Hodgkin lymphoma and concomitant Fanconi anemia and Li-Fraumeni syndrome. Cancer Genetics, 2020, 256-257, 179-183.	0.4	1
312	Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo― Supportive Care in Cancer, 2020, 28, 5125-5137.	2.2	1
313	Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A+AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL). Blood, 2018, 132, 1644-1644.	1.4	1
314	In Vitro Expanded MSCs From Patients with Myeloprliferative Neoplasms at Late Passages Show Recurrent Cytogenetic Abnormalities. Blood, 2010, 116, 4101-4101.	1.4	1
315	Dna Methylation Is Linked to a Specific Cell-Adhesion Program in Relapsed Pediatric t(8;21)(q22;q22)RUNX1-RUNX1T1 Patients. Blood, 2016, 128, 1524-1524.	1.4	1
316	A Potent Thymic Function Is Associated with a Low Risk of Relapse In Leukemia Patients Treated with Haploidentical Stem Cell Transplantation. Blood, 2010, 116, 1258-1258.	1.4	1
317	C029 HLA-identical umbilical cord blood transplantation from a sibling donor in juvenile myelomonocytic leukemia. Leukemia Research, 2009, 33, S48-S49.	0.8	0
318	Biological individuality and the new frontiers of immunological tolerance in hematopoietic stem cell transplantation. Haematologica, 2010, 95, 1447-1451.	3.5	0
319	Reply to "Ethical concerns surrounding the conception of an HLA-compatible child for medical purposes" Haematologica 2012;97(9):e33. Haematologica, 2012, 97, e36-e36.	3.5	O
320	Discarded fraction from bone marrow erythrocyte depletion procedure is a good source of multipotent mesenchymal stromal cells. Cytotherapy, 2013, 15, 879-880.	0.7	0
321	Possible alternatives to antimicrobial therapies. Early Human Development, 2014, 90, S16-S18.	1.8	0
322	Response. Biology of Blood and Marrow Transplantation, 2017, 23, 2014-2015.	2.0	0
323	Bone Marrow Microenvironment in Light-Chain Amyloidosis: In Vitro Expansion and Characterization of Mesenchymal Stromal Cells. Biomedicines, 2021, 9, 1523.	3.2	0
324	A Complex Karyotype but Not Monosomy 7 Is an Independent Prognostic Factor in Advanced Childhood MDS Blood, 2007, 110, 2452-2452.	1.4	0

#	Article	IF	CITATIONS
325	BRAF Mutations in Juvenile Myelomonocytic Leukemia Blood, 2007, 110, 4602-4602.	1.4	O
326	Gene Expression Profile Analysis of Pediatric MDS Patients Correlates with FAB Classification and Has Prognostic Relevance. Blood, 2008, 112, 2695-2695.	1.4	0
327	STAT5 Phosphorylation Status by Flow Cytometry Is a Rapid and Reliable Tool for Diagnosis and Follow-up of Juvenile Myelomonocytic Leukemia. Blood, 2010, 116, 2751-2751.	1.4	0
328	Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia. Blood, 2011, 118, 2797-2797.	1.4	0
329	Mosaic Distribution of RAS Pathway Mutated and Non Mutated Cells in Bone Marrow of Juvenile Myelomonocytic Leukemia Blood, 2012, 120, 2818-2818.	1.4	0
330	NOVEL Recurrent Genetic Aberrations in Pediatric AML: An AIEOP AML-2002 Study Group Blood, 2012, 120, 2494-2494.	1.4	0
331	Unrelated Cord Blood Transplantation For Infant Acute Leukemia Diagnosed Within 1 Year Of Age: Outcomes and Risk Factor Analysis On Behalf Of Eurocord and PDWP-EBMT. Blood, 2013, 122, 160-160.	1.4	0
332	High Dose Imatinib Is Effective In Children and Adolescents With Chronic Myelogenous Leukemia In Chronic Phase. The Italian Experience. Blood, 2013, 122, 1490-1490.	1.4	0
333	Phenotypical, Functional and Genetic Characterization of Mesenchymal Stem Cells Derived from the Spleen of Patients with Myelofibrosis. Blood, 2014, 124, 3227-3227.	1.4	0
334	Role of Allogeneic Hematopoietic Stem Cell Transplantation in t(4;11) Positive Acute Lymphoblastic Leukemia (ALL): A Retrospective Multicenter Study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Blood, 2014, 124, 1243-1243.	1.4	0
335	Intrabone Injection of T-Cell Depleted Peripheral Blood Stem Cells from HLA-Haploidentical Donors to Reduce the Risk of Graft Rejection in Children. Blood, 2014, 124, 1146-1146.	1.4	0
336	Response to High Dose Imatinib and Long-Term Outcome in Children and Adolescents with Previously Untreated Chronic Myeloid Leukemia in Chronic Phase. the Italian Experience. Blood, 2014, 124, 1812-1812.	1.4	0
337	Results of an AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Randomized Clinical Trial in Children with Low- and Intermediate-Risk Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 65-65.	1.4	0
338	Outcome of BONE Marrow Transplantation in Congenital Diskeratosis: Preliminary DATA from the European Group for BONE Marrow Transplantation (EBMT). Blood, 2015, 126, 3623-3623.	1.4	0
339	Hematopoietic Stem Cell Transplantation for Hemophagocytic Lymphohistiocitosis: A National Retrospective Analysis of Data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Blood, 2015, 126, 621-621.	1.4	0
340	Prognostic Role of Minimal Residual Disease before and after Hematopoietic Stem Cell Transplantation in Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1413-1413.	1.4	0
341	HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age. Blood, 2016, 128, 4691-4691.	1.4	0
342	Applications of Haploidentical SCT in Pediatric Patients. Pancreatic Islet Biology, 2017, , 149-178.	0.3	0

#	ARTICLE	IF	CITATIONS
343	Outcome of Transformed Fanconi Anaemia Patients after Hematopoietic Stem Cell Transplantation: Analysis on Behalf of European Group for Blood and Marrow Transplantation. Blood, 2018, 132, 646-646.	1.4	0
344	The Optimal Alternative Donor Transplant for Pediatric Patients with Acute Leukemia: A Comparison between Alfa-Beta T-Cell and B-Cell Depleted Haplo-SCT and UCBT. Blood, 2018, 132, 3462-3462.	1.4	0
345	Busulfan, Cyclophosphamide and Melphalan As Conditioning Regimen for Pediatric Patients with AML in 1st or 2nd CR: A Retrospective Analysis from the AIEOP HSCT Registry. Blood, 2018, 132, 2106-2106.	1.4	0
346	HHV-6 Infection/Reactivation after Allogeneic Stem Cell Transplantation in Pediatric Patients: Epidemiology, Risk Factors and Outcome. Blood, 2018, 132, 3362-3362.	1.4	0
347	Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT. British Journal of Haematology, 2022, , .	2.5	0